Search results
Results from the WOW.Com Content Network
The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the ...
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [ 1 ]
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. [1] It targets interferon a. [2] Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials. [3] [4] [5]
Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. SLE is a disease in which the immune system attacks the body's own cells and tissues. It can affect various organs or systems of the body.
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.. Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" [6] via a process called trogocytosis. [3]
%PDF-1.3 %Äåòåë§ó ÐÄÆ 4 0 obj /Length 5 0 R /Filter /FlateDecode >> stream x ...
A task force of the European League Against Rheumatism (EULAR) made recommendations on preferred terminology. [6] Accordingly, calcium pyrophosphate deposition (CPPD) is an umbrella term for the various clinical subsets, whose naming reflects an emphasis on particular features.
Cutaneous vasculitis is the most common type of vasulitis amongst those with systemic lupus erythematosus. [7] The clinical presentation is variable and can include superficial ulcerations, splinter hemorrhages, panniculitis, macules, erythema with necrosis or erythematous plaques, cutaneous infarction, livedo reticularis, bullous lesions of the extremities or urticaria lesions, papulonodular ...